Behaviors and Mental Disorders

All Conditions

Quality of Life

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Angiogenesis Inhibitors

Oxaliplatin

Endostar protein

Endostatins

Antimetabolites

Growth Inhibitors

Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.

Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.

Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.

oxaliplatin + capecitabine (XELOX chemotherapy)

Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.

rebombniant human endostatin

Ke Xie, MD PhD

ke xie, MD PhD

Xiong jingyan

To study safety and efficacy of intravenous pump of recombinant human endostatin combined with XELOX-treated and also investigate the potential value of CECs level for the prediction of PD and outcomes in patients with advanced colorectal cancer.

Patients were randomly assigned to receive either three treatment cycles of intravenous pump of recombinant human endostatin before chemotherapy.

Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.

Effect of Intravenous Pump of Recombinant Human Endostatin Combined With XELOX Chemotherapy, and a Potential Prognostic Biomarkers in Patient With Advanced Colorectal Cancer

Evaluate the effect of XELOX therapy with or without recombinant human endostatin on progression free survival

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.	NCT03577392	Quality of Life	oxaliplatin + c... rebombniant hum...	18 Years - 75 Years	Sichuan Provincial People's Hospital
Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.	NCT03577392	Quality of Life	oxaliplatin + c... rebombniant hum...	18 Years - 75 Years	Sichuan Provincial People's Hospital

Spots Global Cancer Trial Database for rebombniant human endostatin